In vitro, EIQPN inhibit the androgen-independent proliferation of various AR-positive prostate cancer cells, and block the tumor growth of androgen-independent prostate cancer cells in xenograft mouse models, indicating EIQPN serves as a potential therapeutic agent for CRPC (Tran et al., 2020). This evidence concerns the gene AR and prostate carcinoma.